en تخصصي Special پژوهشي orginal article <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Background & Aims</span></i></b><b><span style="font-size:9.0pt">: </span></b>&nbsp;<span style="font-size:9.0pt">As the first randomized clinical trial, this study evaluated the effect of Famotidine on the improvement of outcomes of hospitalized patients with COVID-19.</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Materials & Methods</span></i></b><b><span style="font-size:9.0pt">:</span></b><span style="font-size:9.0pt"> This phase III randomized clinical trial which was designed with two parallel arms, is a placebo-controlled, single-blind, and concealed allocation study, and recruited 20 patients (10 of them received Famotidine as treatment group and 10 received Placebo as control group). Oral Famotidine 160&nbsp;mg four times a day was given to the COVID-19 patients until the discharge day or for a maximum of 14 days. Patients&rsquo; temperature, respiration rate, oxygen saturation, lung infiltration, lactate dehydrogenase (LDH) level, and complete blood count (CBC) were measured at the baseline (before the intervention) and on day 14 after the intervention or on discharge day. Length of stay in the hospital and length of stay in the ICU were also measured as secondary outcomes of the study.</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Results</span></i></b><b><span style="font-size:9.0pt">:</span></b><span style="font-size:9.0pt"> The results showed a significant decrease in LDH (P=0.01), mean WBC (P=0.04) and length of stay (P=0.04) of patients with COVID-19 in the group treated with Famotidine compared to the control group. There was also a significant increase in oxygen saturation (P=0.01) in the group treated with Famotidine compared to the control group. Cough improvement was also higher in the oral Famotidine group compared to the control group (P=0.02).</span></span></span></span><br> <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><b><i><span style="font-size:9.0pt">Conclusion</span></i></b><b><span style="font-size:9.0pt">: </span></b><span style="font-size:9.0pt">This was the first clinical trial on the effect of Famotidine on the improvement of hospitalized COVID-19 patients, which indicated that high-dose Famotidine improves patients&rsquo; clinical signs and reduces the severity of the disease and duration of hospitalization.</span></span></span></span> Famotidine, COVID-19, Hospitalization 75 82 http://ijrabms.umsu.ac.ir/browse.php?a_code=A-10-152-2&slc_lang=en&sid=1 Hamid Reza Samimagham samimagham@yahoo.com 10031947532846002667 10031947532846002667 No 1Clinical Research Development Center, Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran Mehdi Hassani Azad mehdihassaniazad@gmail.com 10031947532846002668 10031947532846002668 No Infectious and Tropical Diseases Research Center,Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran Mohsen Arabi drmohsenarabi@gmail.com 10031947532846002669 10031947532846002669 No Department of Internal Medicine and Public Health Research Center,Family Medicine Department,Iran University of Medical Sciences,Tehran, Iran Dariush Hooshyar dariush.hooshyar@gmail.com 10031947532846002670 10031947532846002670 No Student Research Comitte,Faculty of Medicie, , Hormozgan University of Medical Sciences, Bandar Abbas, Iran Mohammad Amin Abbasi Amin.abbasi1314@gmail.com 10031947532846002671 10031947532846002671 No Firoozabadi Hospital Clinical Research Development Center, Iran University of Medical Sciences, Tehran, Iran Maryam Haddad Dr.maryhd@gmail.com 10031947532846002672 10031947532846002672 No Clinical Research Development Center, Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran Mitra KazemiJahromi mitra.kazemijahromi@gmail.com 10031947532846002673 10031947532846002673 Yes Endocrinology and Metablism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran